vs
ADMA BIOLOGICS, INC.（ADMA）与艾伯维（ARGX）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是ADMA BIOLOGICS, INC.的17.8倍（$2.5B vs $139.2M）。ADMA BIOLOGICS, INC.净利率更高（35.5% vs 35.5%，领先0.0%）。艾伯维同比增速更快（83.2% vs 18.4%）。艾伯维自由现金流更多（$322.4M vs $34.6M）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
艾伯维是总部位于美国伊利诺伊州北芝加哥的制药企业，研发生产的药物覆盖多种疾病治疗领域，可满足多元临床需求，致力于为全球不同病症的患者提供可靠的治疗方案选择。
ADMA vs ARGX — 直观对比
营收规模更大
ARGX
是对方的17.8倍
$139.2M
营收增速更快
ARGX
高出64.8%
18.4%
净利率更高
ADMA
高出0.0%
35.5%
自由现金流更多
ARGX
多$287.8M
$34.6M
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $2.5B |
| 净利润 | $49.4M | $877.2M |
| 毛利率 | 63.8% | 89.5% |
| 营业利润率 | 45.1% | 28.9% |
| 净利率 | 35.5% | 35.5% |
| 营收同比 | 18.4% | 83.2% |
| 净利润同比 | -55.9% | 1.3% |
| 每股收益（稀释后） | $0.20 | $13.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMAARGX
| Q4 25 | $139.2M | $2.5B | ||
| Q3 25 | $134.2M | — | ||
| Q2 25 | $122.0M | $1.8B | ||
| Q1 25 | $114.8M | — | ||
| Q4 24 | $117.5M | $1.4B | ||
| Q3 24 | $119.8M | — | ||
| Q2 24 | $107.2M | $901.9M | ||
| Q1 24 | $81.9M | — |
净利润ADMAARGX
| Q4 25 | $49.4M | $877.2M | ||
| Q3 25 | $36.4M | — | ||
| Q2 25 | $34.2M | $414.8M | ||
| Q1 25 | $26.9M | — | ||
| Q4 24 | $111.9M | $865.6M | ||
| Q3 24 | $35.9M | — | ||
| Q2 24 | $32.1M | $-32.5M | ||
| Q1 24 | $17.8M | — |
毛利率ADMAARGX
| Q4 25 | 63.8% | 89.5% | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | 89.2% | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | 90.2% | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | 89.4% | ||
| Q1 24 | 47.8% | — |
营业利润率ADMAARGX
| Q4 25 | 45.1% | 28.9% | ||
| Q3 25 | 38.0% | — | ||
| Q2 25 | 35.1% | 19.2% | ||
| Q1 25 | 30.4% | — | ||
| Q4 24 | 32.6% | 8.7% | ||
| Q3 24 | 33.1% | — | ||
| Q2 24 | 36.6% | -15.4% | ||
| Q1 24 | 26.7% | — |
净利率ADMAARGX
| Q4 25 | 35.5% | 35.5% | ||
| Q3 25 | 27.1% | — | ||
| Q2 25 | 28.1% | 23.4% | ||
| Q1 25 | 23.4% | — | ||
| Q4 24 | 95.2% | 64.1% | ||
| Q3 24 | 30.0% | — | ||
| Q2 24 | 29.9% | -3.6% | ||
| Q1 24 | 21.7% | — |
每股收益（稀释后）ADMAARGX
| Q4 25 | $0.20 | $13.25 | ||
| Q3 25 | $0.15 | — | ||
| Q2 25 | $0.14 | $6.32 | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.45 | $13.33 | ||
| Q3 24 | $0.15 | — | ||
| Q2 24 | $0.13 | $-0.55 | ||
| Q1 24 | $0.08 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $3.5B |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $7.3B |
| 总资产 | $624.2M | $8.7B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMAARGX
| Q4 25 | $87.6M | $3.5B | ||
| Q3 25 | $61.4M | — | ||
| Q2 25 | $90.3M | $2.1B | ||
| Q1 25 | $71.6M | — | ||
| Q4 24 | $103.1M | $1.5B | ||
| Q3 24 | $86.7M | — | ||
| Q2 24 | $88.2M | $1.4B | ||
| Q1 24 | $45.3M | — |
总债务ADMAARGX
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $11.0M | ||
| Q1 24 | — | — |
股东权益ADMAARGX
| Q4 25 | $477.3M | $7.3B | ||
| Q3 25 | $431.2M | — | ||
| Q2 25 | $398.3M | $6.1B | ||
| Q1 25 | $373.4M | — | ||
| Q4 24 | $349.0M | $5.5B | ||
| Q3 24 | $231.9M | — | ||
| Q2 24 | $188.3M | $4.3B | ||
| Q1 24 | $153.7M | — |
总资产ADMAARGX
| Q4 25 | $624.2M | $8.7B | ||
| Q3 25 | $568.7M | — | ||
| Q2 25 | $558.4M | $7.2B | ||
| Q1 25 | $510.6M | — | ||
| Q4 24 | $488.7M | $6.2B | ||
| Q3 24 | $390.6M | — | ||
| Q2 24 | $376.4M | $4.8B | ||
| Q1 24 | $350.9M | — |
负债/权益比ADMAARGX
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $323.3M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $322.4M |
| 自由现金流率自由现金流/营收 | 24.8% | 13.0% |
| 资本支出强度资本支出/营收 | 0.8% | 0.0% |
| 现金转化率经营现金流/净利润 | 0.72× | 0.37× |
| 过去12个月自由现金流最近4个季度 | $27.8M | $594.5M |
8季度趋势，按日历期对齐
经营现金流ADMAARGX
| Q4 25 | $35.6M | $323.3M | ||
| Q3 25 | $13.3M | — | ||
| Q2 25 | $21.1M | $361.8M | ||
| Q1 25 | $-19.7M | — | ||
| Q4 24 | $50.2M | $41.9M | ||
| Q3 24 | $25.0M | — | ||
| Q2 24 | $45.6M | $-124.7M | ||
| Q1 24 | $-2.2M | — |
自由现金流ADMAARGX
| Q4 25 | $34.6M | $322.4M | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | $356.6M | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | $40.9M | ||
| Q3 24 | $24.0M | — | ||
| Q2 24 | $43.6M | $-125.5M | ||
| Q1 24 | $-4.6M | — |
自由现金流率ADMAARGX
| Q4 25 | 24.8% | 13.0% | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | 20.1% | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | 3.0% | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 40.7% | -13.9% | ||
| Q1 24 | -5.6% | — |
资本支出强度ADMAARGX
| Q4 25 | 0.8% | 0.0% | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 2.0% | 0.3% | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 2.3% | 0.1% | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.9% | 0.1% | ||
| Q1 24 | 2.9% | — |
现金转化率ADMAARGX
| Q4 25 | 0.72× | 0.37× | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | 0.87× | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | 0.05× | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
